vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and NeuroPace Inc (NPCE). Click either name above to swap in a different company.

NeuroPace Inc is the larger business by last-quarter revenue ($26.6M vs $20.6M, roughly 1.3× Pulmonx Corp). NeuroPace Inc runs the higher net margin — -10.3% vs -66.3%, a 56.1% gap on every dollar of revenue. On growth, NeuroPace Inc posted the faster year-over-year revenue change (23.9% vs -8.7%). Over the past eight quarters, NeuroPace Inc's revenue compounded faster (21.1% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

NeuroPace Inc is a medical technology company focused on developing and commercializing innovative implantable neurostimulation systems to treat neurological disorders, primarily drug-resistant epilepsy. Its core RNS System delivers personalized responsive stimulation to reduce seizure frequency, serving patients across North America and select global markets via partnerships with healthcare providers.

LUNG vs NPCE — Head-to-Head

Bigger by revenue
NPCE
NPCE
1.3× larger
NPCE
$26.6M
$20.6M
LUNG
Growing faster (revenue YoY)
NPCE
NPCE
+32.5% gap
NPCE
23.9%
-8.7%
LUNG
Higher net margin
NPCE
NPCE
56.1% more per $
NPCE
-10.3%
-66.3%
LUNG
Faster 2-yr revenue CAGR
NPCE
NPCE
Annualised
NPCE
21.1%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
NPCE
NPCE
Revenue
$20.6M
$26.6M
Net Profit
$-13.7M
$-2.7M
Gross Margin
77.9%
77.4%
Operating Margin
-40.9%
-6.6%
Net Margin
-66.3%
-10.3%
Revenue YoY
-8.7%
23.9%
Net Profit YoY
5.5%
48.0%
EPS (diluted)
$-0.33
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
NPCE
NPCE
Q1 26
$20.6M
Q4 25
$22.6M
$26.6M
Q3 25
$21.5M
$27.4M
Q2 25
$23.9M
$23.5M
Q1 25
$22.5M
$22.5M
Q4 24
$23.8M
$21.5M
Q3 24
$20.4M
$21.1M
Q2 24
$20.8M
$19.3M
Net Profit
LUNG
LUNG
NPCE
NPCE
Q1 26
$-13.7M
Q4 25
$-10.4M
$-2.7M
Q3 25
$-14.0M
$-3.5M
Q2 25
$-15.2M
$-8.7M
Q1 25
$-14.4M
$-6.6M
Q4 24
$-13.2M
$-5.3M
Q3 24
$-14.1M
$-5.5M
Q2 24
$-15.3M
$-7.5M
Gross Margin
LUNG
LUNG
NPCE
NPCE
Q1 26
77.9%
Q4 25
77.6%
77.4%
Q3 25
74.7%
77.4%
Q2 25
72.1%
77.1%
Q1 25
72.5%
77.0%
Q4 24
74.0%
75.4%
Q3 24
73.7%
73.2%
Q2 24
73.7%
73.4%
Operating Margin
LUNG
LUNG
NPCE
NPCE
Q1 26
-40.9%
Q4 25
-43.8%
-6.6%
Q3 25
-66.9%
-9.5%
Q2 25
-62.0%
-29.0%
Q1 25
-64.6%
-22.9%
Q4 24
-56.5%
-17.0%
Q3 24
-69.3%
-20.1%
Q2 24
-75.2%
-32.4%
Net Margin
LUNG
LUNG
NPCE
NPCE
Q1 26
-66.3%
Q4 25
-46.1%
-10.3%
Q3 25
-64.9%
-12.8%
Q2 25
-63.6%
-36.8%
Q1 25
-64.1%
-29.3%
Q4 24
-55.4%
-24.5%
Q3 24
-69.4%
-25.9%
Q2 24
-73.7%
-39.0%
EPS (diluted)
LUNG
LUNG
NPCE
NPCE
Q1 26
$-0.33
Q4 25
$-0.25
$-0.08
Q3 25
$-0.34
$-0.11
Q2 25
$-0.38
$-0.26
Q1 25
$-0.36
$-0.21
Q4 24
$-0.33
$-0.16
Q3 24
$-0.36
$-0.19
Q2 24
$-0.39
$-0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
NPCE
NPCE
Cash + ST InvestmentsLiquidity on hand
$61.6M
$61.1M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$45.8M
$19.0M
Total Assets
$120.0M
$105.6M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
NPCE
NPCE
Q1 26
$61.6M
Q4 25
$69.8M
$61.1M
Q3 25
$76.5M
$60.0M
Q2 25
$75.5M
$62.1M
Q1 25
$74.6M
$66.3M
Q4 24
$70.9M
$52.8M
Q3 24
$63.3M
$56.8M
Q2 24
$63.5M
$55.5M
Total Debt
LUNG
LUNG
NPCE
NPCE
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
LUNG
LUNG
NPCE
NPCE
Q1 26
$45.8M
Q4 25
$54.1M
$19.0M
Q3 25
$60.0M
$18.5M
Q2 25
$69.1M
$19.4M
Q1 25
$77.7M
$24.3M
Q4 24
$85.8M
$8.0M
Q3 24
$93.9M
$9.8M
Q2 24
$101.2M
$9.9M
Total Assets
LUNG
LUNG
NPCE
NPCE
Q1 26
$120.0M
Q4 25
$129.3M
$105.6M
Q3 25
$138.3M
$107.3M
Q2 25
$147.2M
$106.1M
Q1 25
$150.7M
$110.2M
Q4 24
$162.8M
$94.6M
Q3 24
$167.4M
$96.3M
Q2 24
$172.6M
$94.4M
Debt / Equity
LUNG
LUNG
NPCE
NPCE
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
NPCE
NPCE
Operating Cash FlowLast quarter
$506.0K
Free Cash FlowOCF − Capex
$409.0K
FCF MarginFCF / Revenue
1.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-11.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
NPCE
NPCE
Q1 26
Q4 25
$-7.1M
$506.0K
Q3 25
$-8.2M
$-1.9M
Q2 25
$-3.9M
$-2.1M
Q1 25
$-13.2M
$-7.5M
Q4 24
$-6.7M
$-4.8M
Q3 24
$-7.2M
$-1.7M
Q2 24
$-5.8M
$-3.9M
Free Cash Flow
LUNG
LUNG
NPCE
NPCE
Q1 26
Q4 25
$-7.1M
$409.0K
Q3 25
$-8.3M
$-2.0M
Q2 25
$-4.0M
$-2.3M
Q1 25
$-13.5M
$-7.5M
Q4 24
$-6.8M
$-4.8M
Q3 24
$-7.7M
$-1.8M
Q2 24
$-6.2M
$-4.0M
FCF Margin
LUNG
LUNG
NPCE
NPCE
Q1 26
Q4 25
-31.4%
1.5%
Q3 25
-38.4%
-7.2%
Q2 25
-16.6%
-9.6%
Q1 25
-60.0%
-33.4%
Q4 24
-28.8%
-22.5%
Q3 24
-37.6%
-8.7%
Q2 24
-30.0%
-20.6%
Capex Intensity
LUNG
LUNG
NPCE
NPCE
Q1 26
Q4 25
0.1%
0.4%
Q3 25
0.4%
0.1%
Q2 25
0.2%
0.7%
Q1 25
1.3%
0.2%
Q4 24
0.5%
0.2%
Q3 24
2.0%
0.5%
Q2 24
2.3%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons